NGM Biopharmaceuticals’ aldafermin failed to hit the primary endpoint in the company’s Phase IIb ALPINE 2/3 trial for non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis.
Uber Technologies Inc. and rival Lyft Inc. on May 24 launched Covid-19 vaccine ride programs in partnership with the White House, offering Americans free rides or discounts for their trips to and from a vaccination site.
Pfizer Inc., Merck & Co. Inc., Roche Holding AG, and other companies are racing to produce the first antiviral pill that people could take at early signs of Covid-19. Their shared goal: filling a key treatment hole by helping people recently infected with the novel coronavirus to avoid becoming seriously ill and needing hospitalization.
Ashfield Engage, part of UDG Healthcare plc., announced the completion of the acquisition of Nuvera LLC, a U.S.-based healthcare consulting firm specializing in patient support programs. Nuvera’s expertise in optimizing the design and build of seamless patient and HCP treatment experiences will enhance Ashfield Engage’s Patient Solutions capabilities and create an end-to-end strategic offering across their client’s product lifecycles.
GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.
CVS Health announced a new Clinical Trial Services business that brings together innovation and experience, driving greater access to clinical trials across the communities the company serves and creating a more efficient, convenient experience to improve participant retention and research effectiveness.
Merck Chief Executive Officer Kenneth Frazier was named CEO of the Year by Chief Executive magazine for his longtime leadership at the pharmaceutical giant.
One day after Bristol Myers Squibb announced a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Artificial Intelligence (AI)-focused biopharma company Exscientia that could hit $1.2 billion.
Bayer AG on May 19 will urge a U.S. judge to give preliminary approval to a controversial $2 billion settlement that would create a framework to resolve future claims that the company’s top-selling Roundup weedkiller causes cancer.
Healthcare advertising agency PRECISIONeffect announced the launch of INFLECTIONeffect, a data-driven discipline that amplifies the uptake of medical advances.
